

Drug Monograph

Drug/Drug **Dxevo® (dexamethasone) oral tablets / Oral Corticosteroid**
 Class: **Agent**
 Prepared for: MO HealthNet
 Prepared by: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Dxevo is available as unit-dose packets of oral tablets at a strength of 1.5 mg. The medication is available in a quantity of 39 tablets for an 11-day treatment course.

Manufacturer: Distributed by: Skylar Laboratories LLC. Canton, MS 39046

Indications: Dxevo is indicated for multiple disease states, most commonly for anti-inflammatory, immunosuppressive and/or endocrine disorders.

Costs: \$232.05 per 39 tablets of Dxevo. Wholesale Acquisition Cost

Summary of Findings: The MO HealthNet Division recommends prior authorization status for this product.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit Clinical Edit

Type of PA Criteria: Increased Risk of ADE Preferred
 Appropriate Indications No PA Required

Prepared By: Tyler Woods PharmD
 Date: May 20, 2019